AstraZeneca’s COVID-19 vaccine data fails to impress Wall Street analysts with its effectiveness in clinical trials

AstraZeneca’s experimental COVID-19 vaccine is the third vaccine to demonstrate it can prevent coronavirus infections in a late-stage clinical trial, though the viral vector-based vaccine is much less efficacious than the other leading vaccine candidates.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.